Protein kinase inhibitors

METAvivor and Ciitizen Announce Partnership and New Clinical Trial Search Tool

Retrieved on: 
Tuesday, December 8, 2020

With the help of Ciitizen, Metavivor can now offer clinical trial search and matching service options to those living with MBC.

Key Points: 
  • With the help of Ciitizen, Metavivor can now offer clinical trial search and matching service options to those living with MBC.
  • "Metavivor is thrilled to partner with Ciitizen to bring this multi-layered clinical trial search tool to the metastatic breast cancer community.
  • METAvivor and Ciitizen are launching a new Clinical Trial Search Tool that makes exploring clinical trials easier and more accessible for stage 4 metastatic breast cancer patients.
  • To learn more about METAvivor and Ciitizen's partnership, please visit Metavivor Clinical Trial Search
    Metavivor Research and Support Inc. is an Annapolis-based, 501(c)(3), volunteer-led, non-profit organization founded by metastatic breast cancer (MBC) patients in 2009.

Curis Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

Retrieved on: 
Tuesday, December 8, 2020

"We also have been pleased by the pace at which our trial partners have been able to enroll patients.

Key Points: 
  • "We also have been pleased by the pace at which our trial partners have been able to enroll patients.
  • We look forward to continuing to advance CA-4948 and reporting additional Phase 1 data in the second half of 2021."
  • The reported preliminary data are from Curis's ongoing open-label, single arm Phase 1 dose escalation 3+3 study of orally administered CA-4948 monotherapy in adult patients with AML or high-risk MDS.
  • CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin's lymphoma and in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes.

Biosight Presents Updated New Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting

Retrieved on: 
Monday, December 7, 2020

A Phase 2b study is ongoing to confirm the promising results obtained in a Phase 1/2a study of aspacytarabine as a single-agent first-line AML therapy.

Key Points: 
  • A Phase 2b study is ongoing to confirm the promising results obtained in a Phase 1/2a study of aspacytarabine as a single-agent first-line AML therapy.
  • For more information regarding the Phase 2b clinical study of BST-236, please visit www.clinicaltrials.gov .
  • Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological malignancies and disorders.
  • A Phase 2 study in relapsed/refractory AML and myelodysplastic syndrome (MDS) will be launched in 2020 under a collaboration agreement recently signed with the European cooperative group, GFM.

BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020

Retrieved on: 
Sunday, December 6, 2020

The data indicates that treatment with the bemcentinib-LDAC combination shows promising efficacy in relapsed patients who are unfit for intensive chemotherapy.

Key Points: 
  • The data indicates that treatment with the bemcentinib-LDAC combination shows promising efficacy in relapsed patients who are unfit for intensive chemotherapy.
  • Richard Godfrey, Chief Executive Officer of BerGenBio, said: "We are pleased to continue sharing updates from our phase II clinical studies assessing bemcentinib with the scientific and medical community.
  • MDS is associated with increased risk of developing AML and immune dysfunctions are seen in patients both with lower and higher-risk MDS.
  • Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme.

BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020

Retrieved on: 
Sunday, December 6, 2020

The data indicates that treatment with the bemcentinib-LDAC combination shows promising efficacy in relapsed patients who are unfit for intensive chemotherapy.

Key Points: 
  • The data indicates that treatment with the bemcentinib-LDAC combination shows promising efficacy in relapsed patients who are unfit for intensive chemotherapy.
  • Richard Godfrey, Chief Executive Officer of BerGenBio, said: "We are pleased to continue sharing updates from our phase II clinical studies assessing bemcentinib with the scientific and medical community.
  • MDS is associated with increased risk of developing AML and immune dysfunctions are seen in patients both with lower and higher-risk MDS.
  • Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme.

Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company’s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020

Retrieved on: 
Thursday, December 3, 2020

It is assessing the safety and tolerability of lasofoxifene in combination with abemaciclib for treating women with locally advanced or metastatic ER+/HER2- breast cancer and an ESR1 mutation.

Key Points: 
  • It is assessing the safety and tolerability of lasofoxifene in combination with abemaciclib for treating women with locally advanced or metastatic ER+/HER2- breast cancer and an ESR1 mutation.
  • Sermonix is partnering with Tempus, a data-driven, precision-medicine technology company, to identify and enroll ELAINE 2 participants through genomic biomarker testing.
  • Sermonix is delighted to share a poster at SABCS 2020 highlighting the study in our collaboration with Eli Lilly and Company, said Dr. Paul Plourde.
  • Sermonix non-executive chairman of the board is Anthony Wild, Ph.D., former president of both Parke-Davis Pharmaceuticals and Warner-Lamberts Pharmaceutical Division.

Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine

Retrieved on: 
Thursday, November 19, 2020

Grade 3 or 4 AEs occurred in 72% of people treated with LORBRENA and 56% of people treated with XALKORI.

Key Points: 
  • Grade 3 or 4 AEs occurred in 72% of people treated with LORBRENA and 56% of people treated with XALKORI.
  • LORBRENA was specifically developed to inhibit tumor mutations that drive resistance to other ALK inhibitors and to penetrate the blood brain barrier.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • Discontinue strong CYP3A inducers for 3 plasma half-lives of the strong CYP3A inducer prior to initiating LORBRENA.

BerGenBio (BGBIO): Initiation - Bemcentinib leading the AXL charge

Retrieved on: 
Tuesday, November 17, 2020

BerGenBio (BGBIO) is a pioneer in AXL biology and the development of AXL inhibitors: selective tyrosine kinase inhibitor (TKI) bemcentinib and functional blocking monoclonal antibody tilvestamab.

Key Points: 
  • BerGenBio (BGBIO) is a pioneer in AXL biology and the development of AXL inhibitors: selective tyrosine kinase inhibitor (TKI) bemcentinib and functional blocking monoclonal antibody tilvestamab.
  • Selective AXL inhibition can prevent and reverse acquired drug resistance and stop immune suppression, potentially augmenting the efficacy of other cancer drug classes.
  • Bemcentinib, an oral once-a-day pill, has demonstrated efficacy in 2L AML and 2L NSCLC, and could be the first selective AXL inhibitor to market.
  • The key drivers are bemcentinib in 2L NSCLC (peak sales $1.2bn, NOK40.7/share) and AML (peak sales $588m, NOK13.3/share) plus COVID-19 opportunity (NOK5.9/share).

BerGenBio (BGBIO): Initiation - Bemcentinib leading the AXL charge

Retrieved on: 
Tuesday, November 17, 2020

BerGenBio (BGBIO) is a pioneer in AXL biology and the development of AXL inhibitors: selective tyrosine kinase inhibitor (TKI) bemcentinib and functional blocking monoclonal antibody tilvestamab.

Key Points: 
  • BerGenBio (BGBIO) is a pioneer in AXL biology and the development of AXL inhibitors: selective tyrosine kinase inhibitor (TKI) bemcentinib and functional blocking monoclonal antibody tilvestamab.
  • Selective AXL inhibition can prevent and reverse acquired drug resistance and stop immune suppression, potentially augmenting the efficacy of other cancer drug classes.
  • Bemcentinib, an oral once-a-day pill, has demonstrated efficacy in 2L AML and 2L NSCLC, and could be the first selective AXL inhibitor to market.
  • The key drivers are bemcentinib in 2L NSCLC (peak sales $1.2bn, NOK40.7/share) and AML (peak sales $588m, NOK13.3/share) plus COVID-19 opportunity (NOK5.9/share).

BioCryst to Present Data at the 2020 ASH Annual Meeting

Retrieved on: 
Thursday, November 12, 2020

RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that preclinical data on BCX9930, an oral Factor D inhibitor, will be presented at the 62nd American Society of Hematology(ASH) Annual Meeting being held as a virtual event, December 5-8, 2020.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that preclinical data on BCX9930, an oral Factor D inhibitor, will be presented at the 62nd American Society of Hematology(ASH) Annual Meeting being held as a virtual event, December 5-8, 2020.
  • ET
    Discovered by BioCryst, BCX9930 is a novel, oral, potent and selective small molecule inhibitor of FactorD currently in Phase 1 clinical development for the treatment of complement-mediated diseases.
  • The U.S. Food and Drug Administration (FDA) has granted both Fast Track status and Orphan Drug designation for BCX9930 in PNH.
  • As a Factor D inhibitor, BCX9930 is designed as an oral monotherapy that can address both intravascular and extravascular hemolysis in PNH patients.